RESUMEN
PURPOSE: Primary mediastinal large B-cell lymphoma with sclerosis (PMLBL) is a rare entity of non-Hodgkin's lymphoma (NHL) arising from thymic mature B cells. Optimal treatment strategies remain to be established, especially in pediatric patients. PATIENTS AND METHODS: This study analyzes clinical characteristics and treatment outcome of 30 pediatric patients with PMLBL, diagnosed in multicenter therapy NHL-Berlin-Frankfurt-Münster Group (BFM) trials. Treatment was stratified by stage and serum lactate dehydrogenase (LDH) and consisted of four to six 5-day courses of chemotherapy using steroids, oxazaphosphorine alkylating agents, methotrexate, cytarabine, etoposide, and doxorubicin. Radiation was not part of the protocol. RESULTS: From April 1986 to August 1999, 1,650 patients with newly diagnosed NHL were enrolled in the NHL-BFM trials; 30 patients (1.8%) had PMLBL. Median age was 14.3 years (range, 1.4 to 16.7 years); 15 patients were male and 15 patients were female. With a median observation time of 5 years (range, 1 to 12 years), probability of event-free survival (pEFS) at 5 years was 0.70 (SE, 0.08). Two patients erroneously diagnosed as T-cell NHL received non-B-cell therapy and died from progress of disease. Events in 28 patients receiving B-cell therapy included early progress during therapy (n = 1) and relapse (n = 6). Residual mediastinal masses were present in 23 patients after two courses of therapy and in 15 patients after the end of therapy. LDH > or = 500 U/L was associated with increased risk of failure in multivariate analysis. CONCLUSION: PMLBL mainly is found in adolescents. Dose-intense chemotherapy including high-dose methotrexate yields a pEFS at 5 years of 0.70 (SE, 0.08). LDH is of prognostic value in pediatric patients with PMLBL.
Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Biomarcadores de Tumor/análisis , Linfoma de Células B/tratamiento farmacológico , Linfoma de Células B Grandes Difuso/tratamiento farmacológico , Adolescente , Corticoesteroides/uso terapéutico , Antineoplásicos Alquilantes/administración & dosificación , Niño , Preescolar , Citarabina/administración & dosificación , Progresión de la Enfermedad , Supervivencia sin Enfermedad , Doxorrubicina/administración & dosificación , Etopósido/administración & dosificación , Femenino , Estudios de Seguimiento , Humanos , Lactante , L-Lactato Deshidrogenasa/análisis , Linfoma de Células B/complicaciones , Linfoma de Células B/patología , Linfoma de Células B Grandes Difuso/complicaciones , Linfoma de Células B Grandes Difuso/patología , Masculino , Metotrexato/administración & dosificación , Pronóstico , Esclerosis/etiología , Esclerosis/patología , Resultado del TratamientoRESUMEN
We describe a patient who concomitantly presented with renal cell carcinoma (RCC) and hairy cell leukemia (HCL). Hairy cells formed atypical cell convolutes on bone marrow smears that might have been mistaken for tumor metastases.
Asunto(s)
Médula Ósea/patología , Carcinoma de Células Renales/patología , Leucemia de Células Pilosas/patología , Anciano , Carcinoma de Células Renales/complicaciones , Carcinoma de Células Renales/diagnóstico , Tamaño de la Célula , Humanos , Leucemia de Células Pilosas/complicaciones , Leucemia de Células Pilosas/diagnóstico , Infiltración Leucémica , MasculinoAsunto(s)
Transformación Celular Neoplásica/genética , Proteínas Nucleares/genética , Proteínas Tirosina Quinasas/genética , Proteínas Tirosina Quinasas Receptoras/genética , Quinasa de Linfoma Anaplásico , Animales , División Celular , Genes ras , Linfoma Anaplásico de Células Grandes/genética , Proteínas Nucleares/metabolismo , Nucleofosmina , Fragmentos de Péptidos , Ratas , Proteínas Tirosina Quinasas Receptoras/metabolismo , Proteínas Recombinantes de Fusión/genética , Proteínas Recombinantes de Fusión/metabolismo , Proteínas Represoras/genética , Proteínas Represoras/metabolismoRESUMEN
Anaplastic large-cell lymphoma (ALCL) accounts for approximately 10% of pediatric non-Hodgkin lymphoma (NHL). Previous experience from NHL-Berlin-Frankfurt-Münster (BFM) trials indicated that the short-pulse B-NHL-type treatment strategy may also be efficacious for ALCL. The purpose of this study was to test the efficacy of this protocol for treatment of childhood ALCL in a large prospective multicenter trial and to define risk factors. From April 1990 to March 1995, 89 patients younger than 18 years of age with newly diagnosed ALCL were enrolled in trial NHL-BFM 90. Immunophenotype was T-cell in 40 patients, B-cell in 5, null in 31, and not determined in 13. Stages were as follows: I, n = 8; II, n = 20; III, n = 55; IV, n = 6. Extranodal manifestations were as follows: mediastinum, n = 28; lung, n = 13; skin, n = 16; soft tissue, n = 13; bone, n = 14; central nervous system, n = 1; bone marrow, n = 5. After a cytoreductive prephase, treatment was stratified into 3 branches: patients in K1 (stage I and II resected) received three 5-day courses (methotrexate [MTX] 0.5 g/m(2), dexamethasone, oxazaphorins, etoposide, cytarabine, doxorubicin, and intrathecal therapy); patients in K2 (stage II nonresected and stage III) received 6 courses; patients in K3 (stage IV or multifocal bone disease) received 6 intensified courses including MTX 5 g/m(2), high-dose cytarabine/etoposide. The Kaplan-Meier estimate for a 5-year event-free survival was 76% +/- 5% (median follow-up, 5.6 years) for all patients and 100%, 73% +/- 6%, and 79% +/- 11% for K1, K2, and K3, respectively. Events were as follows: progression during therapy, n = 2; progression or relapse after therapy, n = 20; second malignancy, n = 1. It was concluded that short-pulse chemotherapy, stratified according to stage, is effective treatment for pediatric ALCL. B symptoms were associated with increased risk of failure. (Blood. 2001;97:3699-3706)
Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/administración & dosificación , Linfoma Anaplásico de Células Grandes/tratamiento farmacológico , Adolescente , Quinasa de Linfoma Anaplásico , Protocolos de Quimioterapia Combinada Antineoplásica/normas , Niño , Preescolar , Supervivencia sin Enfermedad , Femenino , Alemania , Humanos , Inmunofenotipificación , Lactante , Linfoma de Células B/tratamiento farmacológico , Linfoma Anaplásico de Células Grandes/diagnóstico , Masculino , Estudios Prospectivos , Proteínas Tirosina Quinasas/metabolismo , Proteínas Tirosina Quinasas Receptoras , Recurrencia , Factores de Riesgo , Insuficiencia del TratamientoRESUMEN
From 1987 to 1999 35 patients with poor prognosis non-Hodgkin's lymphoma (NHL) underwent allogeneic stem cell transplantation (SCT) at the University Hospitals of Vienna and Graz. Initial biopsy specimens were reclassified according to the Revised European-American Classification of Lymphoid Neoplasms (REAL). All patients surviving 28 days engrafted. Twenty-eight of them (93%) attained clinical remission. At the last follow-up 14 patients were alive and disease-free at a median of 5.0 (range, 2.3-12.9) years after allogeneic SCT. The actuarial overall survival is 35%. Five patients relapsed 1.8 to 27.6 months after transplant, the probability of relapse is 23%. Of the 21 deaths following SCT, seven were due to relapse/refractory disease and 14 due to transplant-related causes. The probability of treatment-related mortality is 48%. After SCT, minimal residual disease (MRD) was monitored by polymerase chain reaction (PCR) in seven patients with a BCL-2/IgH translocation and in 13 with a clonal immunoglobulin heavy chain (IgH) rearrangement. All 20 patients attained clinical remission rapidly and converted to PCR negativity. In the follow-up nine of these patients are in long-term clinical and molecular remission, six PCR-negative patients died of transplant-related causes and five patients relapsed. In summary, allogeneic stem cell transplantation has a curative potential for patients with refractory and recurrent non-Hodgkin's lymphoma. In our series long-term disease-free survival was associated with molecular disease eradication after SCT. Treatment-related mortality rate was high, thus earlier referral of selected patients to allogeneic SCT should be considered.
Asunto(s)
Trasplante de Células Madre Hematopoyéticas , Linfoma no Hodgkin/terapia , Adulto , Femenino , Reordenamiento Génico , Genes de Inmunoglobulinas , Genes bcl-2 , Enfermedad Injerto contra Huésped/etiología , Humanos , Cadenas Pesadas de Inmunoglobulina/genética , Linfoma no Hodgkin/genética , Linfoma no Hodgkin/mortalidad , Masculino , Persona de Mediana Edad , Reacción en Cadena de la Polimerasa , Pronóstico , Trasplante HomólogoRESUMEN
Inflammatory mediators were shown to exert procoagulant effects on cultured human endothelial cells (EC). In the present study the effect of intradermal application of tumor necrosis factor-alpha (TNF-alpha) on the expression of factors involved in regulation of coagulation at the EC surface, i.e. tissue factor (TF), thrombomodulin (TM) and tissue factor pathway inhibitor (TFPI) was studied in humans in vivo. The endothelial expression of these factors was evaluated immunohistochemically in biopsies taken after intradermal application of 5000 U TNF-alpha in 8 healthy volunteers. After 6 and 22 h biopsies were taken from the injection sites. At TNF-alpha injected sites typical inflammatory changes. e.g. EC upregulation of adhesion molecules and accumulation of leukocytes were detected. In parallel we could document EC expression of TF, downregulation of TM and depletion of tissue factor pathway inhibitor (TFPI) in inflamed areas. Early depletion of endothelial IkappaB alpha at the site of inflammation after application of TNF-alpha points to an activation of the NF-kappaB pathway. Our data suggest that, as shown in in vitro experiments, TNF-alpha activates the NF-kappaB pathway and induces specific procoagulant changes of EC due to expression of TF, down-regulation of TM and depletion of TFPI in vivo in humans. This procoagulant shift in the haemostatic balance on the cell surface, caused by TNF-alpha-induced inflammation, is likely to contribute to thrombosis associated with tissue inflammation in humans.
Asunto(s)
Endotelio Vascular/efectos de los fármacos , Hemostasis/efectos de los fármacos , Inflamación/metabolismo , Factor de Necrosis Tumoral alfa/farmacología , Adolescente , Adulto , Anticoagulantes/metabolismo , Biopsia , Factores de Coagulación Sanguínea/metabolismo , Método Doble Ciego , Endotelio Vascular/metabolismo , Humanos , Inmunohistoquímica , Inflamación/inducido químicamente , Inyecciones Intradérmicas , Lipoproteínas/efectos de los fármacos , Lipoproteínas/metabolismo , Masculino , FN-kappa B/efectos de los fármacos , Piel/irrigación sanguínea , Piel/patología , Trombomodulina/efectos de los fármacos , Trombomodulina/metabolismo , Tromboplastina/efectos de los fármacos , Tromboplastina/metabolismo , Factor de Necrosis Tumoral alfa/administración & dosificación , Factor de von Willebrand/efectos de los fármacos , Factor de von Willebrand/metabolismoRESUMEN
The expression of the surface molecule CD38 on B cell chronic lymphocytic leukemia (B-CLL) cells has recently been described as a prognostic marker for patient survival. We have analyzed CD19/CD38 expression in 81 patients with predominantly early stages of B-CLL (69 Binet A, seven Binet B, five Binet C). Sixty-two patients (77%) had less than 30% CD38+/CD19+ cells, while 19 (23%) had > or = 30%. There was a significant association between Binet stages (A vs. B+C, p < 0.0001), Rai stages (0-II vs. III+IV, p < 0.001) and CD38 expression, confirming the published cut-off level of 30%. A particularly strong association between CD38 expression was found with soluble CD23 (sCD23) levels of > or = 2000 U/ml (p < 0.0001) and beta2-microglobulin (beta2 MG) serum levels of > or = 3 mg/l (p < 0.0001) indicating that CD38 is a marker of tumor mass as well as disease progression. A borderline association was found with lymphocyte doubling time (LDT) < 12 months (p = 0.05) due to low patient numbers, while there was no association with age, sex or immunoglobulin deficiency. Discordant results were obtained in a number of patients: 10 of 69 patients (14%) with Binet A had a CD38 > or = 30% while three of seven patients with Binet B had a CD38 < 30%. In these two subgroups CD38 and other prognostic factors gave discrepant results. Due to the early stage and short median observation time (12 months. range 1-24 months), calculations concerning patient survival were not performed. However, our data show a strong association between CD38 and other known prognostic factors. The results also suggest that this factor is not always reliable in Binet A patients.
Asunto(s)
Antígenos CD , Antígenos de Diferenciación/análisis , Leucemia Linfocítica Crónica de Células B/metabolismo , NAD+ Nucleosidasa/análisis , ADP-Ribosil Ciclasa , ADP-Ribosil Ciclasa 1 , Anciano , Antígenos CD19/análisis , Femenino , Humanos , Leucemia Linfocítica Crónica de Células B/mortalidad , Leucemia Linfocítica Crónica de Células B/terapia , Masculino , Glicoproteínas de Membrana , Persona de Mediana Edad , Estadificación de Neoplasias , PronósticoRESUMEN
Acute human immunodeficiency virus (HIV) infection is a transient illness that typically presents with mucocutaneous and constitutional symptoms. It is soon followed by seroconversion with the detection of anti-HIV antibodies in the peripheral blood. To better understand the pathogenetic events leading to this clinical picture, we sought to investigate the (immuno)histologic features of the skin rash occurring in an acutely infected person. A skin biopsy of an acutely infected person was investigated histologically and immunohistologically using paraffin-embedded tissue sections. Interface dermatitis with pronounced vacuolization of the basal keratinocytes was a prominent histological finding. The inflammatory infiltrate was composed of CD3+/CD8+ T cells with coexpression of Granzyme B7 and TIA-1, and CD68+ histiocytes/dendritic cells. CD1a+ intraepidermal Langerhans cells (LC) were significantly decreased and individual LC coexpressed HIV-p24 antigens as evidenced in double labeling experiments. HIV-infected LC were demonstrated in close apposition to cytotoxic T cells. This study provides the first definitive evidence for infection of LC at extramucosal sites in this very early stage of disease. Our findings emphasize the critical role of dendritic cells as a virus reservoir and the skin as a major site of HIV replication during the course of the disease.
Asunto(s)
Exantema/patología , Infecciones por VIH/patología , VIH-1/patogenicidad , Células de Langerhans/patología , Enfermedad Aguda , Adulto , Antivirales/uso terapéutico , Quimioterapia Combinada , Exantema/etiología , Exantema/virología , Anticuerpos Anti-VIH/sangre , Antígenos VIH/análisis , Infecciones por VIH/sangre , Infecciones por VIH/complicaciones , Infecciones por VIH/tratamiento farmacológico , Seropositividad para VIH , VIH-1/aislamiento & purificación , Homosexualidad Masculina , Humanos , Inmunohistoquímica , Queratinocitos/patología , Queratinocitos/virología , Células de Langerhans/virología , Masculino , Reacción en Cadena de la Polimerasa de Transcriptasa InversaRESUMEN
Drug resistance of non-Hodgkin's lymphomas may involve mechanisms of the multidrug resistance phenotype including the lung resistance protein (LRP) and the multidrug resistance protein (MRP1). To determine the clinical relevance of these multidrug resistance factors in previously untreated diffuse large B-cell lymphomas (n = 48), we studied LRP and MRP1 expression in lymphoma cells and their impact on clinical outcome. LRP and MRP1 expression were immunohistochemically assessed by means of the monoclonal antibodies LRP-56 and MRPr1, respectively. LRP was positive in 23% and MRP1 in 44% of the samples. LRP expression was associated with higher tumor stage (P = 0.03), elevated serum lactate dehydrogenase levels (P = 0.01), and the International Prognostic Index (P = 0.0001). LRP-positive patients had a lower complete response rate to polychemotherapy than LRP-negative patients (18 versus 65%; P = 0.006). Patients with LRP expression had a shorter overall survival than those without LRP expression (median of 0.9 years versus median not reached; P = 0.001). MRP1 expression was independent of clinical and laboratory parameters and had no impact on the outcome of chemotherapy or survival of the patients. These data suggest that LRP expression but not MRP1 expression is an important mechanism of drug resistance associated with worse clinical outcome in previously untreated diffuse large B-cell lymphomas. Thus, the reversal of LRP-mediated drug resistance may improve clinical outcome in diffuse large B-cell lymphoma in the future.
Asunto(s)
Transportadoras de Casetes de Unión a ATP/biosíntesis , Linfoma de Células B/tratamiento farmacológico , Linfoma de Células B/metabolismo , Linfoma de Células B Grandes Difuso/tratamiento farmacológico , Linfoma de Células B Grandes Difuso/metabolismo , Proteínas de Neoplasias/biosíntesis , Partículas Ribonucleoproteicas en Bóveda/biosíntesis , Análisis de Varianza , Protocolos de Quimioterapia Combinada Antineoplásica/administración & dosificación , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Bleomicina/administración & dosificación , Ciclofosfamida/administración & dosificación , Citarabina/administración & dosificación , Doxorrubicina/administración & dosificación , Resistencia a Múltiples Medicamentos , Etopósido/administración & dosificación , Femenino , Humanos , Inmunohistoquímica , Lomustina/administración & dosificación , Masculino , Metotrexato/administración & dosificación , Persona de Mediana Edad , Proteínas Asociadas a Resistencia a Múltiples Medicamentos , Prednimustina/administración & dosificación , Prednisona/administración & dosificación , Análisis de Regresión , Análisis de Supervivencia , Resultado del Tratamiento , Vincristina/administración & dosificaciónRESUMEN
The Shwachman-Diamond syndrome (SDS) is a rare congenital disorder for which inheritance by an autosomal recessive trait has been suggested. Shwachman-Diamond syndrome is defined by exocrine pancreatic insufficiency combined with severe neutropenia. Moreover, SDS patients are at risk to develop neoplastic hematologic diseases. We describe 2 SDS-affected daughters of consanguine parents who were born 1 year apart, at 35 and 36 weeks of gestation, and who died at the age of 4 and 3.5 months, respectively, due to respiratory infections. Histologic bone marrow evaluation of the second-born child revealed a diffuse proliferation of immature B cells, which comprised 40% of the total cellularity. These cells were identified as precursor B cells by immunophenotyping studies (CD79a(+)/CD10(+)/CD20(-)/CD22(-)/CD34(-)/ terminal deoxynucleotidyl transferase(-)). Molecular determination of the immunoglobulin heavy-chain gene status did not reveal clonality. The emergence of this peculiar B-cell population was interpreted as a marked increase of hematogones. Although the clinical significance and the exact function of hematogones is still obscure, they may play a critical regenerative role in the regulation of hemopoiesis, but without malignant potential in SDS. Immunophenotyping and molecular studies, therefore, have potential value in the differential diagnosis of primary bone marrow failures. This report adds SDS to the spectrum of conditions in which a prominent number of hematogones may be observed.
Asunto(s)
Linfocitos B/patología , Células de la Médula Ósea/patología , Moléculas de Adhesión Celular , Insuficiencia Pancreática Exocrina/congénito , Células Madre Hematopoyéticas/patología , Lectinas , Neutropenia/congénito , Antígenos CD/análisis , Antígenos CD20/análisis , Antígenos CD34/análisis , Antígenos de Diferenciación de Linfocitos B/análisis , Linfocitos B/inmunología , Células de la Médula Ósea/inmunología , Antígenos CD79 , Consanguinidad , ADN Nucleotidilexotransferasa/análisis , Insuficiencia Pancreática Exocrina/complicaciones , Insuficiencia Pancreática Exocrina/patología , Resultado Fatal , Femenino , Trastornos del Crecimiento/complicaciones , Trastornos del Crecimiento/patología , Células Madre Hematopoyéticas/inmunología , Humanos , Inmunofenotipificación , Lactante , Neprilisina/análisis , Neutropenia/complicaciones , Neutropenia/patología , Receptores de Antígenos de Linfocitos B/análisis , Lectina 2 Similar a Ig de Unión al Ácido Siálico , SíndromeRESUMEN
PURPOSE: Recent metaphase cytogenetic studies suggested that specific chromosomal abnormalities are of prognostic significance in patients with multiple myeloma (MM). Because the true incidence of chromosomal abnormalities in MM is much higher than that detected by metaphase analysis, we used interphase fluorescence in situ hybridization (FISH) to determine the prognostic value of specific chromosomal aberrations. PATIENTS AND METHODS: Bone marrow plasma cells from 89 previously untreated patients with MM were studied consecutively by FISH to detect the deletions of 13q14, 17p13, and 11q and the presence of t(11;14)(q13;q32). FISH results were analyzed in the context of clinical parameters (response to treatment and survival after conventional-dose chemotherapy), and a multivariate analysis of prognostic factors was performed. RESULTS: By FISH, the deletion of 13q14 occurred in 40 patients (44.9%), deletion of 17p13 in 22 (24.7%), and 11q abnormalities in 14 (15.7%; seven with t(11;14)). Deletions of 13q14 and 17p13 were associated with poor response to induction treatment (46.9% v 77.3% in those without deletions, P =.006 and 40.0% v 73.2%, P =.008, respectively) and short median overall survival (OS) time (24.2 v 88.1 months, P =. 008 and 16.2 v 51.3 months, P =.008, respectively). Short median OS time was also observed for patients with 11q abnormalities (13.1 v 41.6 months, P =.02). According to the number of unfavorable cytogenetic features (deletion of 13q14, deletion of 17p13, and aberrations of 11q) that were present in each patient (0 v 1 v 2 or 3), patients with significantly different OS times could be discriminated from one another (102.4 v 29.6 v 13.9 months, P <.001, respectively). CONCLUSION: For patients with MM who were treated with conventional-dose chemotherapy, interphase FISH for 13q14, 17p13, and 11q provides prognostically relevant information in addition to that provided by standard prognostic factors. This observation may be considered for risk-adapted stratifications of MM patients in future clinical trials.
Asunto(s)
Aberraciones Cromosómicas/genética , Interfase/genética , Mieloma Múltiple/genética , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Células de la Médula Ósea/patología , Deleción Cromosómica , Trastornos de los Cromosomas , Cromosomas Humanos Par 11/genética , Cromosomas Humanos Par 13/genética , Cromosomas Humanos Par 17/genética , Citogenética , Femenino , Predicción , Humanos , Hibridación Fluorescente in Situ , Incidencia , Masculino , Metafase/genética , Persona de Mediana Edad , Mieloma Múltiple/tratamiento farmacológico , Mieloma Múltiple/patología , Análisis Multivariante , Células Plasmáticas/patología , Pronóstico , Análisis de Regresión , Inducción de Remisión , Tasa de Supervivencia , Trisomía/genéticaRESUMEN
BACKGROUND: The major diagnostic role of peripheral lymphocyte subset typing is to distinguish between malignant and reactive conditions. METHODS: The present study evaluates the screening efficacy of flow cytometric lymphocyte subset typing for the presence of a lymphoid malignancy. Four hundred samples were analyzed with a combination of anti-T-, B-, and natural killer (NK)-cell monoclonal antibodies. RESULTS: Two hundred and twenty (55%) samples showed a normal distribution of lymphocyte subsets, 73 (18%) samples exhibited unspecific alterations of lymphocyte subsets, 19 (5%) samples exhibited a reactive phenotype typical of Epstein-Barr virus/cytomegalovirus (EBV/CMV) infection, and 88 (22%) samples expressed a phenotype suggestive of lymphoma. The most predictive independent factor of a lymphoma-specific phenotype was the absolute lymphocyte count (P = 0.0001, odds ratio 73.225). Seventy-eight percent of samples containing >/=4 x 10(9)/l lymphocytes and 2% of samples with lymphocyte counts <4 x 10(9)/l exhibited a lymphoma-specific phenotype. The specificity of the referring clinical comment was the second best predictor of a lymphoma-specific typing outcome (P = 0.0001, odds ratio 19.589). The independent predictive values of lymphocyte morphology and of relative lymphocyte counts were of borderline significance. CONCLUSIONS: The use of flow cytometric lymphocyte subset typing as a diagnostic screening method for lymphoma should be restricted to cases of unexplained elevation of absolute lymphocyte counts with or without morphological atypias and to cases with definite clinical symptoms of lymphoma.
Asunto(s)
Neoplasias Hematológicas/diagnóstico , Inmunofenotipificación , Subgrupos Linfocitarios/inmunología , Linfoma/diagnóstico , Infecciones por Citomegalovirus/inmunología , Diagnóstico Diferencial , Infecciones por Virus de Epstein-Barr/inmunología , Citometría de Flujo/métodos , Neoplasias Hematológicas/inmunología , Humanos , Recuento de Linfocitos , Linfoma/inmunología , Tamizaje Masivo/métodos , Oportunidad RelativaRESUMEN
Current treatment of patients with myelodysplastic syndrome (MDS) is unsatisfactory. Very recently, immunosuppressive treatment strategies have been gaining interest. We report a patient with transfusion-dependent MDS who achieved significant hematopoietic improvement following cyclosporine (CsA) therapy and who is now transfusion independent for more than 5 years. This single observation supports the view that CsA, among other immunosuppressive agents, could play an important role in future treatment concepts in MDS and may lead to clinically relevant and sustained improvement of hematopoiesis in a subset of patients.
Asunto(s)
Ciclosporina/uso terapéutico , Hematopoyesis/efectos de los fármacos , Inmunosupresores/uso terapéutico , Síndromes Mielodisplásicos/tratamiento farmacológico , Adulto , Anemia Refractaria/tratamiento farmacológico , Anemia Refractaria/inmunología , Médula Ósea/efectos de los fármacos , Médula Ósea/patología , Ciclosporina/efectos adversos , Transfusión de Eritrocitos , Estudios de Seguimiento , Humanos , Inmunosupresores/efectos adversos , Masculino , Síndromes Mielodisplásicos/inmunología , Transfusión de Plaquetas , Resultado del TratamientoRESUMEN
Since the detection that platelets originate from megakaryocytes (MK), the site of megakaryocyte fragmentation has been disputed. Some authors have even postulated that platelets are solely produced in the lungs. Thus, we have directly measured platelet generation in the bone marrow (BM) by comparing the relative number of young RNA-containing, so-called reticulated platelets (%RP) in the BM and in the peripheral blood (PB). Two separate prospective, cross sectional trials have been conducted in patients routinely undergoing BM biopsies for diagnostic purposes. In the first part of the study 30 patients with stem cell or bone marrow transplantation were examined. The second part of the study was performed in 62 haematological patients visiting the outpatient's clinic. Median %RP were higher in BM than in PB (p <0.001). In the second part of the study the difference averaged 133% (interquartile range: 30-383%). There was a moderate correlation between %RP in BM and in PB (r = 0.67; p <0.001). The absolute number of RP in PB correlated weakly with the number of megakaryocytes (0.42; p = 0.001), which was due to a correlation between the platelet counts and the megakaryocyte counts (r = 0.55; p <0.001 in biopsies). Two patients with autoimmune antibodies against GPIIb/IIIa exhibited 10% and 16% RP in PB, and had 29% and 59% RP in BM, respectively. It is concluded that the relative number of RP is significantly higher in BM than in blood. This supports the notion that platelets are at least in part released from MK in the bone marrow, particularly in patients suffering from immune thrombocytopenia.
Asunto(s)
Plaquetas/patología , Células de la Médula Ósea/patología , Enfermedades Hematológicas/patología , ARN/análisis , Antígenos de Superficie/sangre , Plaquetas/química , Estudios Transversales , Femenino , Enfermedades Hematológicas/genética , Neoplasias Hematológicas/genética , Neoplasias Hematológicas/patología , Humanos , Isoantígenos/sangre , Masculino , Megacariocitos/citologíaRESUMEN
In order to determine the relationship between bone marrow (bm) endosteal cells (EDC) and hemopoietic progenitors, we have analyzed the immunophenotype of EDC using various antibodies (Ab) against mesenchymal antigens. The Ab were applied on paraffin sections of normal bm (iliac crest, n=17; talus, n=1; phalanx, n=1), myeloregenerative bm (after chemotherapy), and hematologic disorders (acute myeloid leukemia (AML), n=8; chronic myeloid leukemia (CML), n=6; myelodysplastic syndromes (MDS), n=14; severe aplastic anemia (SAA), n=4; essential thrombocythemia (ET), n=2; idiopathic (primary) osteomyelo-fibrosis (IMF), n=1; polycythemia vera (PV), n=1). In normal bm, EDC were found to react with Ab against vimentin, tenascin, alpha-smooth muscle actin, osteocalcin, CD51, and CD56, but did not react with Ab against CD3, CD15, CD20, CD34, CD45, CD68, or CD117. An identical phenotype of EDC was found in AML, MDS, SAA, ET, IMF, PV, myeloregenerative bm, and peripheral bones lacking active hemopoiesis (talus, phalanx). In patients with CML, EDC reacted with Ab to CD51, but did not react with Ab to CD56. Based on their unique antigen profile, EDC were enriched from normal bm by enzyme digestion and cell sorting. However, these enriched cells (CD56+, CD45-, CD34-) did not give rise to hemopoietic cells under the culture conditions used, i.e. in the presence of the growth factors IGF-1, bFGF, SCF, IL-3, and GM-CSF Together, our data do not support the hypothesis that EDC are totipotent mesenchymal progenitors giving rise to hemopoietic cells.
Asunto(s)
Células de la Médula Ósea/química , Células de la Médula Ósea/inmunología , Inmunofenotipificación , Antígenos CD/análisis , Células de la Médula Ósea/efectos de los fármacos , Células de la Médula Ósea/metabolismo , Antígeno CD56/análisis , Células Cultivadas , Sustancias de Crecimiento/farmacología , Hematopoyesis/efectos de los fármacos , Células Madre Hematopoyéticas/química , Células Madre Hematopoyéticas/efectos de los fármacos , Células Madre Hematopoyéticas/inmunología , Células Madre Hematopoyéticas/metabolismo , Humanos , Integrina alfaV , Células Madre/efectos de los fármacos , Células Tumorales CultivadasRESUMEN
Acute myeloid leukemia following organ transplantation (PT-AML) is a rare event with only a few published cases in the literature. We present three patients who developed AML (FAB M1, M5, M4) after renal, double lung or liver transplantation. Molecular analysis detected a t(9;11) in one patient and documented the recipient origin of AML in a second patient. All patients were treated with chemotherapy. Immunosuppression was reduced to cyclosporin A (CsA) and prednisone in two patients and to prednisone alone in one patient. Two patients achieved a complete remission (CR), with a remission duration of 4.6 months in one patient, the other patient died from septicemia after 15.2 months in CR. One patient was refractory to chemotherapy and died from septicemia. This report together with the documented cases in the literature suggests that PT-AML (1) develops after a median interval of 5 years after transplantation with variable latency (range, <1-17 years); (2) is heterogeneous with respect to FAB classification; (3) shows chromosomal and molecular changes typical of therapy-related AML (t-AML: -7, +8, 11q23, inv16, t(15;17)); (4) standard chemotherapy is feasible after reduction of immunosuppression and produces a CR rate of 56% with a median remission duration of 4.6 months and an overall survival of 2.6 months; (5) the major complications are early death (25%), gram-negative septicemia, progressive disease or relapse. This review provides diagnostic and therapeutic experiences and guidelines for the management of this increasing group of post-transplant patients.
Asunto(s)
Inmunosupresores/efectos adversos , Trasplante de Riñón/inmunología , Leucemia Mieloide/etiología , Trasplante de Hígado/inmunología , Trasplante de Pulmón/inmunología , Enfermedad Aguda , Anciano , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Humanos , Inmunofenotipificación , Leucemia Mieloide/tratamiento farmacológico , Leucemia Mieloide/inmunología , Masculino , Persona de Mediana EdadRESUMEN
We studied 42 intestinal T-cell lymphomas (ITLs) to establish a simple and reproducible classification. The ITLs were classified into pleomorphic small cell (n = 3), monomorphic medium-sized cell (n = 10), pleomorphic medium and large cell (n = 17), immunoblastic (n = 1), and anaplastic large cell (n = 9) lymphomas. Two cases were unclassifiable. Overlapping histologic features were noted between some cases and also within the same tumor and between multiple lesions of the same patient. Histologic evidence of enteropathy was present in most cases. The ITLs expressed cytoplasmic CD3 and antigens associated with cytolytic function (TIA-1, granzyme B), but not CD4 and CD5. Six of the 10 monomorphic medium-sized cell lymphomas were CD56+ T-cell lymphomas. Because of the histologic heterogeneity in some ITLs, we suggest a classification system with 2 main categories: (1) small to medium-sized cell, comprising pleomorphic small and monomorphic medium-sized cell lymphomas; and (2) large cell, comprising the remaining subtypes. The differential diagnosis includes B-cell lymphomas, tumors of histiocytic origin, anaplastic carcinoma, and malignant melanoma.
Asunto(s)
Neoplasias Intestinales/patología , Linfoma de Células T/patología , Antígeno CD56 , Diagnóstico Diferencial , Humanos , Inmunofenotipificación , Neoplasias Intestinales/clasificación , Neoplasias Intestinales/inmunología , Linfoma de Células T/clasificación , Linfoma de Células T/inmunologíaRESUMEN
Recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) is widely used in the treatment or prevention of neutropenia induced by cytostatic regimens. Recent studies with this cytokine have shown several local and/or systemic side effects. We herein report on four patients with different tumor entities receiving GM-CSF as a part of their intensified cytostatic regimen. All four patients developed immune phenomena (sicca syndrome, seropositive arthralgia, hyperthyroidism, and pneumonitis, respectively) during or after subcutaneous treatment with GM-CSF. Pathologic alterations in immunologic serum parameters as well as histopathologic findings accompanied the clinical symptoms. These observations suggest that the therapeutic application of GM-CSF might be involved in the clinical emergence of autoimmune diseases.
Asunto(s)
Enfermedades Autoinmunes/inducido químicamente , Factor Estimulante de Colonias de Granulocitos y Macrófagos/efectos adversos , Neoplasias/tratamiento farmacológico , Adulto , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Autoanticuerpos/análisis , Enfermedades Autoinmunes/patología , Neoplasias de la Mama/tratamiento farmacológico , Neoplasias de la Mama/patología , Femenino , Factor Estimulante de Colonias de Granulocitos y Macrófagos/uso terapéutico , Humanos , Masculino , Persona de Mediana Edad , Neoplasias/patología , Neutropenia/inducido químicamente , Neutropenia/tratamiento farmacológico , Proteínas Recombinantes , Sarcoma/tratamiento farmacológico , Sarcoma/patologíaRESUMEN
We used a new combined chemo- (COP/ABVD), radiation and interferon-alpha (10 x 10(6) IU s.c. 3x per week/12 months) therapy regimen to treat severe multicentric Castleman's disease (CD) complicated by relapsing Behcet's disease (BD) manifestations. More than 16 years after diagnosis of CD the patient remains in very good clinical condition, with remission of all CD and BD manifestations 13 months after discontinuation of the interferon-alpha treatment. In addition, our clinicopathological, immunohistological and virological data suggest a pathogenetic link between CD and BD via activation of pre-existing BD-specific plasma cells due to CD-related HHV8-induced overexpression of interleukin-6.
Asunto(s)
Antineoplásicos/uso terapéutico , Síndrome de Behçet/complicaciones , Enfermedad de Castleman/terapia , Interferón-alfa/uso terapéutico , Adulto , Enfermedad de Castleman/complicaciones , Enfermedad de Castleman/radioterapia , Terapia Combinada , Herpesvirus Humano 8/aislamiento & purificación , Humanos , Interleucina-6/metabolismo , Masculino , Recurrencia , Sarcoma de Kaposi/complicacionesRESUMEN
A subset of patients with systemic mastocytosis (SM) develop acute myeloid leukaemia (AML). However, little is known about the biology of such leukaemias and their relationship to the mast cell (MC) lineage. We report on two female patients who suffered from SM and AML. According to FAB criteria, the leukaemias were classified as AML-M4 (patient 1) and AML-MO (patient 2). The coexistence of the two distinct neoplasms (AML and SM) was demonstrable by immunostaining of serial bone marrow (BM) sections with monoclonal antibodies (mAb). In particular, the MC infiltrates were found to react with mAb against MC-tryptase and MC growth factor receptor c-kit (CD117), but not with mAb to CD15 or CD34. In contrast, the AML blasts were immunoreactive for CD15 (patient 1) or CD34 (patient 2), but did not express tryptase. The c-kit point mutation Asp-->Val at codon 816, considered to play a role in the transformation of MC progenitors, was detected in patient 1 in a BM cell fraction containing 4% MC. However, no c-kit mutation was found in pure AML blasts (<1% MC). These findings argue against an evolution of the AML clone from neoplastic MC or MC-committed progenitors.